Business Wire

HONG-KONG-SCIENCE

24.3.2023 03:01:29 CET | Business Wire | Press release

Share
HKSTP Reveals Startup Semi-finalists for Annual Global EPiC Pitch Competition

Hong Kong is open to all and Hong Kong Science and Technology Parks Corporation (HKSTP) is ramping up its seventh Elevator Pitch Competition (EPiC 2023) by unveiling its 50 Grand Finale semi-finalists, selected from 618 entries and 55 economies across the world.

EPiC 2023 -- backed by innovation-driven partners Cathay, HSBC, MTR Lab, plus world-leading accelerator Plug & Play -- is the city’s most eagerly anticipated pitch event each year and will take place on 28 April 2023 (Friday) at the summit of Hong Kong’s tallest building, the International Commerce Centre. The annual event is a unique, worldwide competition for mid to late-stage startups in the FinTech and PropTech sectors who seek to expand their footprints into Asia and beyond, while leveraging Hong Kong’s biggest innovation ecosystem at HKSTP.

EPiC provides the best available platform for startups to make real business impact through connections with the Science Park network of 1,000+ investors and 300+ corporate partners.

This year, three quarters of the entries are from overseas, with the proportion of overseas contestants and the number of economies participating hitting a record high since 2016. A total of 50 contestants representing 14 different economies entered the semi-final round.

All 50 semi-finalists have a golden opportunity to be considered for direct investment of up to US$5 million from the HKSTP Venture Fund, as well as market expansion support across Asia and beyond, plus the chance to win a cash prize of US$90,000 if crowned overall champion.

Albert Wong, CEO, HKSTP, said: “EPiC is an iconic mega event that has hit global scale, as record turnout from international startups further demonstrates Hong Kong’s advantages as an international I&T hub. Hong Kong is diversified, vibrant and attracts the very best entrepreneurs, investors and corporate innovators. Grow fast and go beyond is the theme for EPiC this year, and we welcome talents from around the world to explore Hong Kong’s unlimited investment and innovation opportunities.”

The EPiC Grand Finale on 28 April will be hosted at Hong Kong’s iconic Sky 100 venue atop Hong Kong’s tallest building, the International Commerce Centre. The 50 competing teams will pitch their world-changing ideas to a judging panel of renowned investors, entrepreneurs, and business leaders. The actual pitch will comprise of a 60-second elevator ride as participants compete for the title of overall EPiC Champion.

To propel EPiC to the broader public, HKSTP has launched for the first time, the "My Favourite Pitcher" public poll, which is open to all to vote for their favourite pitch video from the shortlisted 50 semi-finalists. The poll is now available at EPiC polling website (epic-voting.hkstp.org) and lasts until 28 April 2023 1pm (HKT). The semi-finalist with the highest number of votes will win the cash prize of US$10,000, plus 200,000 Asia Miles sponsored by Cathay.

HKSTP will also kick off the exclusive Immersion Programme for semi-finalists to experience Hong Kong’s I&T ecosystem first-hand and unlock business opportunities through educational talks, business matching and networking with leading corporate partners and investors across the HKSTP ecosystem.

Contestants Breakdown:

Category

No. of applicants

PropTech

266 (43%)

FinTech

352 (57%)

Headquarter

No. of applicants

Overseas

465 (75%)

Hong Kong

153 (25%)

A record high proportion of overseas contestants and economies participation since 2016.

EPiC activities:

Now until 28 April 2023, 1pm (HKT)

"My Favourite Pitcher" Public Polling

  • The top 50 semi-finalists' pitching videos is open for public online voting
  • The semi-finalist with the highest number of votes will be crowned EPiC 2023's "My Favourite Pitcher" and win the cash prize of US$10,000 plus 200,000 Asia Miles sponsored by Cathay

25 – 26 April 2023

"Grow Beyond Hong Kong" Immersion Programme

  • An exclusive 2-day programme for EPiC 2023 semi-finalists to experience HKSTP’s innovation ecosystem.
  • Participants will unlock growth opportunities through educational talks, business matching and networking with leading corporate partners and investors in our ecosystem.

28 April 2023

EPiC 2023 Grand Finale

  • Venue: Sky100 Hong Kong Observation Deck
  • Top 50 Semi-Finalists will pitch their ideas within a 60-second elevator ride
  • Top 10 Finalists will pitch their innovation ideas on stage to renowned investors, entrepreneurs, and business leaders
  • All 50 semi-finalists have the golden opportunities to be considered for direct investment of up to US$5 million from the HKSTP Venture Fund, plus the chance to win a cash prize of US$90,000 if crowned overall champion.

For more information on EPiC 2023, please visit: https://epic.hkstp.org/

For full list of the 50 semi-finalists see appendix below.

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to two unicorns and Hong Kong’s leading R&D hub with over 12,000 research professionals and over 1,200 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.

Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.

Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.

More information about HKSTP is available at www.hkstp.org.

APPENDIX:

50 semi-finalists for the Grand Finale of EPiC 2023, with 26 from FinTech and 24 from PropTech:

FinTech

Company Name (in alphabetical order)

Headquarter

1

AlgoBot Limited

Hong Kong SAR China

2

Amuro Limited

Hong Kong SAR China

3

Canvasland Limited

Hong Kong SAR China

4

Deland Labs

Singapore

5

Doconomy

Sweden

6

Dowsure

Mainland China

7

Endangered Wildlife OÜ

Estonia

8

FedML, Inc.

United States

9

FinCrime Dynamics

United Kingdom

10

Finema

Thailand

11

FINGREEN AI

France

12

PFY Healthcare Technology

Mainland China

13

Homebase

Vietnam

14

Leapstack

Vietnam

15

Miotech

Mainland China

16

Prometheus Technologies

United States

17

Redkik

United States

18

Revix

United Kingdom

19

Sensor data

Mainland China

20

Health Exchange Technology Service Group

Mainland China

21

Speedlegal

United States

22

Taos Technology LLC

United States

23

Ultipa

Mainland China

24

VoiceAI Technologies

Mainland China

25

Vymo

United States

26

Wequity

Belgium

PropTech

Company Name (in alphabetical order)

Headquarter

1

Archifiction

Mainland China

2

Bridge5 Asia

Singapore

3

Collov, Inc

United States

4

Dfocus

Mainland China

5

Doratoon

Singapore

6

EGG Lighting

United Kingdom

7

Firefly Dimension, Inc.

United States

8

FLX Solutions

United States

9

I2Cool Limited

Hong Kong SAR China

10

IronYun

United States

11

Kodifly Limited

Hong Kong SAR China

12

Layer Construction, Inc.

United States

13

Llewellyn and Partners Company Limited

Hong Kong SAR China

14

Mimicrete

United Kingdom

15

PassiveLogic

United States

16

Photinique Limited

Hong Kong SAR China

17

Rootie

Israel

18

SKYLAND INNOVATION COMPANY LIMITED

Hong Kong SAR China

19

Structure Pal

Israel

20

Swiss AI

Switzerland

21

Tensorflight, Inc.

United States

22

Umi Coating New Material Technology Co., Limited

Hong Kong SAR China

23

Visionaries 777

Hong Kong SAR China

24

VoltSafe Inc.

Canada

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230324005001/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye